Back to Search
Start Over
Sofosbuvirābased direct acting antiviral therapies for patients with hepatitis C virus genotype 2 infection
- Source :
- Journal of Gastroenterology and Hepatology. 34:1620-1625
- Publication Year :
- 2019
- Publisher :
- Wiley, 2019.
-
Abstract
- BACKGROUND AND AIM Data regarding the comparative effectiveness and safety of sofosbuvir (SOF) in combination with ribavirin (RBV), daclatasvir (DCV), or ledipasvir (LDV) for hepatitis C virus genotype 2 (HCV-2) patients were limited. We aimed to evaluate the performance of these regimens in Taiwan. METHODS One hundred eighty-seven HCV-2 patients with compensated liver diseases receiving SOF in combination with RBV (n = 82), DCV (n = 66), or LDV (n = 39) for 12 weeks were retrospectively enrolled. The effectiveness was determined by sustained virologic response 12 weeks off therapy (SVR12 ). The patient characteristics potentially related to SVR12 were compared. The safety profiles and laboratory abnormalities were assessed. RESULTS The SVR12 rates were 93.9% (95% confidence interval [CI]: 86.5-97.4%), 98.5% (95% CI: 91.9-99.7%), and 100% (95% CI: 91.0-100%) in patients receiving SOF combined with RBV, DCV, and LDV, respectively. All patients tolerated treatment well. The stratified SVR12 rates were comparable regardless of baseline characteristics or week 4 viral decline among these regimens. Six (3.2%) patients had serious adverse events which were not related to treatment. The rates of fatigue, pruritus, and anemia tended to be higher in patients receiving RBV (22.0%, 19.5%, and 8.5%) combination than those receiving DCV (10.6%, 6.1%, and 1.5%) or LDV (10.3%, 5.1%, and 0%) combination. CONCLUSIONS Sofosbuvir in combination with RBV, DCV, or LDV for 12 weeks is effective and well-tolerated for HCV-2 patients. Compared with DCV or LDV combination, the risks of fatigue, pruritus, and anemia are higher in patients receiving RBV combination.
- Subjects :
- Male
Ledipasvir
Comparative Effectiveness Research
medicine.medical_specialty
Pyrrolidines
Time Factors
Daclatasvir
Genotype
Sustained Virologic Response
Sofosbuvir
Anemia
Hepatitis C virus
Taiwan
Hepacivirus
medicine.disease_cause
Antiviral Agents
Gastroenterology
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Internal medicine
Ribavirin
medicine
Humans
Adverse effect
Aged
Retrospective Studies
Fluorenes
Hepatology
business.industry
Imidazoles
Valine
Hepatitis C, Chronic
Middle Aged
medicine.disease
Confidence interval
Treatment Outcome
chemistry
030220 oncology & carcinogenesis
Benzimidazoles
Female
030211 gastroenterology & hepatology
Carbamates
Uridine Monophosphate
business
medicine.drug
Subjects
Details
- ISSN :
- 14401746 and 08159319
- Volume :
- 34
- Database :
- OpenAIRE
- Journal :
- Journal of Gastroenterology and Hepatology
- Accession number :
- edsair.doi.dedup.....12162a68dcabf0043dc0c703ccac064c
- Full Text :
- https://doi.org/10.1111/jgh.14615